U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of ... - Pfizer
https://www.pfizer.com/und/news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer
WebApr 4, 2019 · IBRANCE is an oral inhibitor of CDKs 4 and 6, 6 which are key regulators of the cell cycle that trigger cellular progression. 7,8 In the U.S., IBRANCE is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination...
DA: 93 PA: 8 MOZ Rank: 93